Damora Therapeutics (DMRA) Other Operating Expenses (2019 - 2025)

Damora Therapeutics' Other Operating Expenses history runs 4 years deep, the most recent figure standing at $174.3 million for Q4 2025.

• Quarterly Other Operating Expenses rose 3866.1% year-over-year to $174.3 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $174.3 million (up 3150.23% YoY) and the FY2025 annual result came in at $174.3 million, up 3150.23% from the prior year.
• Other Operating Expenses was $174.3 million for Q4 2025 at Damora Therapeutics, up from $4.4 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $174.3 million in Q4 2025 and bottomed at $720000.0 in Q4 2023.
• A 3-year average of $36.6 million and a median of $2.7 million in 2023 frame the typical range for Other Operating Expenses.
• Annual changes were most pronounced in 2024 — Other Operating Expenses jumped 510.42% — and 2025, when it surged 3866.1%.
• Damora Therapeutics' Other Operating Expenses stood at $720000.0 in 2023, then soared by 510.42% to $4.4 million in 2024, then jumped by 3866.1% to $174.3 million in 2025.
• Business Quant data shows DMRA's Other Operating Expenses at $174.3 million in Q4 2025, $4.4 million in Q4 2024, and $968000.0 in Q2 2024.